Earlier this month, Scioto Biosciences, Inc. began their Phase Ib clinical trial of SB-121 for the treatment of Autistic DIsorder (AD).
The trial is a multiple-dose, randomized, double-blind, placebo-controlled, cross-over single-site study and will include patients ages 15-45 diagnosed with AD. The primary goal of this study are to determine the safety and pharmacokinetics of SB-121 — the first ABT to began clinical tersting.
Business Wire published the official press release on August 18, 2021. In this press release, Scioto Biosciences CEO, Joe Trebley, PhD, stated:
“This study is an important milestone in our understanding of how the microbiome effects the gut-brain axis in patients with AD. It will significantly advance our efforts to potentially develop SB-121 as a therapy for patients with AD by providing critical safety data in this patient population.”
If you would like to learn more about the SB-121 clinical trial (NCT04944901), please visit ClinicalTrials.gov.
About Scioto Biosciences, Inc.
Scioto Biosciences is revolutionizing the field of microbiome therapeutics. The company has developed a novel Activated Bacterial Therapeutic (ABT) platform designed to deliver live therapeutic bacteria to the gastrointestinal (GI) tract. With this approach, Scioto hopes to treat GI disease by improving mucosal barrier function. Currently, Scioto is developing ABTs for a variety of diseases, including preterm infant guy dysbiosis, Clostridium difficile infection, childhood obesity, and other neurological and metabolic disorders. To learn moer about Scioto Biosciences, please visit their website: https://sciotobiosciences.com/.